OBJECTIVE: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. METHOD: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment withfluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. RESULTS: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; chi = 3.86, p =.049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. CONCLUSIONS: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.
RCT Entities:
OBJECTIVE: We present results of a feasibility test of a sequential treatment strategy using continuation phase cognitive-behavioral therapy (CBT) to prevent relapse in youths with major depressive disorder (MDD) who have responded to acute phase pharmacotherapy. METHOD: Forty-six youths (ages 11-18 years) who had responded to 12 weeks of treatment with fluoxetine were randomized to receive either 6 months of continued antidepressant medication management (MM) or antidepressant MM plus relapse prevention CBT (MM+CBT). Primary outcome was time to relapse, defined as a Childhood Depression Rating Scale-Revised score of 40 or higher and 2 weeks of symptom worsening or clinical deterioration warranting alteration of treatment to prevent full relapse. RESULTS: Cox proportional hazards regression, adjusting for depression severity at randomization and for the hazard of relapsing by age across the trial, revealed that participants in the MM treatment group had a significantly greater risk for relapse than those in the MM+CBT treatment group (hazard ratio = 8.80; 95% confidence interval 1.01-76.89; chi = 3.86, p =.049) during 6 months of continuation treatment. In addition, patient satisfaction was significantly higher in the MM+CBT group. No differences were found between the two treatment groups on attrition rate, serious adverse events, and overall global functioning. CONCLUSIONS: These preliminary results suggest that continuation phase CBT reduces the risk for relapse by eightfold compared with pharmacotherapy responders who received antidepressant medication alone during the 6-month continuation phase.
Authors: John March; Susan Silva; Stephen Petrycki; John Curry; Karen Wells; John Fairbank; Barbara Burns; Marisa Domino; Steven McNulty; Benedetto Vitiello; Joanne Severe Journal: JAMA Date: 2004-08-18 Impact factor: 56.272
Authors: E Jane Costello; Daniel S Pine; Constance Hammen; John S March; Paul M Plotsky; Myrna M Weissman; Joseph Biederman; H Hill Goldsmith; Joan Kaufman; Peter M Lewinsohn; Martha Hellander; Kimberly Hoagwood; Doreen S Koretz; Charles A Nelson; James F Leckman Journal: Biol Psychiatry Date: 2002-09-15 Impact factor: 13.382
Authors: Paul A Nakonezny; Carroll W Hughes; Taryn L Mayes; Kathryn H Sternweis-Yang; Betsy D Kennard; Matthew J Byerly; Graham J Emslie Journal: J Child Adolesc Psychopharmacol Date: 2010-10 Impact factor: 2.576
Authors: Robert Z Blaha; Anne B Arnett; Michael W Kirkwood; H Gerry Taylor; Terry Stancin; Tanya M Brown; Shari L Wade Journal: J Head Trauma Rehabil Date: 2015 May-Jun Impact factor: 2.710
Authors: Joan Rosenbaum Asarnow; Martha C Tompson; Alexandra M Klomhaus; Kalina Babeva; David A Langer; Catherine A Sugar Journal: J Child Psychol Psychiatry Date: 2019-12-15 Impact factor: 8.982
Authors: Betsy D Kennard; Graham J Emslie; Taryn L Mayes; Paul A Nakonezny; Jessica M Jones; Aleksandra A Foxwell; Jessica King Journal: Am J Psychiatry Date: 2014-10 Impact factor: 18.112